Rexall Sundown fourth-quarter sales rise 25%; earnings double.
This article was originally published in The Tan Sheet
Executive SummaryREXALL SUNDOWN FISCAL FOURTH-QUARTER SALES UP 25% to $51.6 mil. on broader distribution of the company's Sundown vitamin line, the firm announced Oct. 10. Income from continuing operations for the three-month period ended Aug. 31 more than doubled (up 108.3%) to $6.5 mil. Rexall reported a net loss of $1.9 mil. in the fourth quarter of fiscal 1995 related to the divestiture of Pennex Labs
You may also be interested in...
Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.